Hematological malignancies (HM) are a group of neoplastic diseases that are usually
heterogenous in nature due to the complex underlying genetic aberrations in which …

Highlights•CRISPR/Cas9 overcomes limitations of earlier targeted nuclease-mediated
methods.•CRISPR/Cas9 allows for insertions/deletions of multiple alleles in a single …

Advances in genome engineering in the last decade, particularly in the development of
programmable nucleases, have made it possible to edit the genomes of most cell types …

Targeted genome editing in hematopoietic stem and progenitor cells (HSPCs) using
CRISPR/Cas9 can potentially provide a permanent cure for hematologic diseases. However …

Clustered regularly interspaced short palindromic repeats (CRISPR) based gene-editing
has begun to transform the treatment landscape of genetic diseases. The history of the …

Bit by bit, over the last few decades, functional genomic tools have been piecing together the
molecular puzzle driving tumorigenesis in human patients. Nevertheless, our understanding …

The recent introduction of clustered regularly interspaced short palindromic repeats
(CRISPR) and CRISPR associated protein (Cas) systems, offer an array of genome and …

The development of programmable nucleases to introduce defined alterations in genomic
sequences has been a powerful tool for precision medicine. While several nucleases such …

Clustered regularly interspaced short palindromic repeats (CRISPR)‐driven genome editing
has rapidly transformed preclinical biomedical research by eliminating the underlying …

Genome editing therapies represent a significant advancement in next‐generation,
precision medicine for the management of haematological diseases, and CRISPR/Cas9 has …